314 related articles for article (PubMed ID: 33270732)
1. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
Szakács Z; Hegyi PJ; Farkas N; Hegyi P; Balaskó M; Erős A; Szujó S; Pammer J; Mosdósi B; Simon M; Nagy A; Für G; Hussain A
PLoS One; 2020; 15(12):e0243045. PubMed ID: 33270732
[TBL] [Abstract][Full Text] [Related]
2. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
3. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
8. Current status and novel strategy of CML.
Morita K; Sasaki K
Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
10. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
11. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
12. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Quintás-Cardama A; Kantarjian H; Cortes J
Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
[TBL] [Abstract][Full Text] [Related]
14. [Chronic Myelogenous Leukemia].
Hochhaus A; Eigendorff E; Ernst T
Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
[TBL] [Abstract][Full Text] [Related]
15. [Chronic myeloid leukemia].
Usui N
Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
[TBL] [Abstract][Full Text] [Related]
17. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
18. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib: Valuable therapeutic option for the Bulgarian market.
Uzunova KH; Filipova EP; Vekov TY
J Cancer Res Ther; 2018; 14(5):909-915. PubMed ID: 30197324
[TBL] [Abstract][Full Text] [Related]
20. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]